Association between vitamin D and uterine fibroids: a study protocol of an open-label, randomised controlled trial

Bo Sheng,1 Yizuo Song,1 Yi Liu,1 Chenchen Jiang,2 Xueqiong Zhu3

ABSTRACT

Introduction Uterine fibroids are the most common pelvic benign tumour with no satisfactory long-term medical treatment. Recent studies have demonstrated that vitamin D significantly inhibited the growth of fibroids in vitro, vivo and a small-sample clinical trial. Therefore, the aim of this randomised clinical trial (RCT) is to evaluate whether supplementation with vitamin D could reduce the risk and inhibit the growth of uterine fibroids in reproductive stage women.

Methods and analysis The open-label, RCT comprises two parts, including part I and II. In part I, 2230 vitamin D deficiency or vitamin D insufficiency patients without uterine fibroids will be randomly assigned to two groups: intervention group (according to the level of serum 25-hydroxyvitamin D3, receive 1600 or 800 IU/day of vitamin D3 for 2 years) and control group (followed up at the same time points). By using gynaecological ultrasound examinations, the incidence of uterine fibroids will be employed to measure the outcome in different groups. In part II, 360 uterine fibroids patients with vitamin D deficiency or vitamin D insufficiency will be randomly assigned to intervention group or control group. According to the level of serum 25-hydroxyvitamin D3, 180 patients will receive 1600 or 800 IU/day of vitamin D3 for 2 years. Control group will receive regular follow-up. The outcome measure will be conducted using gynaecological ultrasound examinations to detect the growth of uterine fibroids in each group.

Ethics and dissemination This study has been approved by the institutional review board of the Second Affiliated Hospital of Wenzhou Medical University (No. LCKY2018-35).

Trial registration numbers NCT03586947 and NCT03584529.

INTRODUCTION

Uterine fibroids (UFs) are the most common benign tumour of the female genital tract, originating from smooth muscle cells.1 Due to diverse diagnostic methods and the population source in many epidemiological studies, the incidence of leiomyomas ranges from 5.4% to 77% of women in their reproductive years.1 Because most patients with UFs remain asymptomatic, the actual incidence of UF is assumed to be much higher than that reported. Based on the ultrasound screening, the incidence for UFs is reported to be 1.278% in Asia and 3.745% in African-American women per year.3 The common symptoms of UFs include heavy menstrual bleeding, menstrual disorders and pelvic discomfort.3 Furthermore, UFs are also associated with infertility and early pregnancy loss. The treatment for UFs depends on the size, location, symptoms, age and reproductive plans. Surgery is still the major treatment for symptomatic UFs including hysterectomy and myomectomy.3 4 Uterine arterial embolisation, one of the conservative interventional treatments with the longest track record, has become the major second line option for UFs patients who are properly selected.3 4 However, these therapies increase the patients’ operative complications and generates huge economic impact on healthcare systems. Except invasive surgical procedure, gonadotropin-releasing hormone agonist (GnRHa)5 6 (eg, leuprolrelin) and mifepristone7 8 are the most commonly used medical agents for UFs in China. When these two drugs are stopped, UFs may regrow rapidly.9 10 Thus, GnRHa or mifepristone is usually used for the clinically symptomatic patients who are at a perimenopausal period, or who have contraindications of surgery. Selective progesterone receptor modulators (SPRMs) act by linkage with progesterone receptors in the smooth muscle of UFs, leading to inhibition of cell proliferation.11

Strengths and limitations of this study

► The results from this randomised clinical trial will provide new evidences of the efficacy and safety of vitamin D for uterine fibroids patients.
► One limitation is that the trial is not a double-blind, placebo-controlled trial and implemented in only one single hospital.
► Another limitation is that the trial is implemented in only one hospital in Chinese subjects, which may limit its generalisability.
In fact, mifepristone is the first SPRM approved to treat UFs. In addition to mifepristone, four types of SPRMs have been developed including asoprisnil, telapristone acetate, ulipristal acetate and vilaprisan. However, these four SPRMs have not been licensed in China to date and are still being investigated in human clinical trials. Therefore, it is still paramount to finding a novel non-surgical alternative for UFs patients and prevent their occurrence.

Vitamin D is one of the essential nutrients for human bodies. Recent studies have considered that vitamin D is involved in the development of UFs. For example, two groups have demonstrated that low levels of serum 25-hydroxyvitamin D are linked with increased risk of UFs. Bläuer et al. found that the growth of both primary myometrial and leiomyoma cells could be inhibited by 1,25-dihydroxyvitamin D in a concentration-dependent way. Moreover, the process of fibrosis induced by the transforming growth factor-β3 (TGF-β3) could be attenuated by vitamin D in immortalised human UFs (HuLM) cells. In addition, vitamin D suppressed the protein expression of plasminogen activator inhibitor-1, which is an important TGF-β target in HuLM cells. Such inhibitory effect of vitamin D on UFs is also verified in several in vivo studies. Halder et al. reported that 1,25-dihydroxyvitamin D decreased fibroid tumour size through downregulation of proliferation-related genes, antiapoptotic genes, oestrogen and progesterone receptors in Eker rats. Two years later, Halder et al. further found that the treatment with 1,25-dihydroxyvitamin D or paricalcitol, an analogue of 1,25-dihydroxyvitamin D, with lower calcemic activity, could reduce tumour size in mouse xenograft models of UFs. Most recently, one study by Corachán et al. demonstrated that vitamin D inhibited the proliferation of human primary uterine leiomyoma cells via cell growth arrest induction and Wnt/β-catenin pathway downregulation. Furthermore, long-term vitamin D treatment significantly decreased the uterine leiomyoma size in a xenograft ovariectomised nonobese diabetic-severe combined immunodeficiency disease (NOD-SCID) mouse model, which confirmed the inhibitory effect of vitamin D on UFs growth in vivo.

Our group has demonstrated that serum 25-hydroxyvitamin D level was significantly lower in patients with UFs as compared with controls. In addition, patients with vitamin D deficiency had increased risks of UFs. An open-label clinical trial indicated that the supplement of vitamin D in women with UFs stabilised the growth of fibroids and prevented the onset of its related symptoms. But it was not a randomised trial and only 108 patients were included in the trial. A recently published randomised clinical trial found that vitamin D consumption did not significantly decrease the volume of fibroids in experimental group compared with control group. However, this new trial was completed shortly with a follow-up period of only 12 weeks. Hence, it is still unclear whether long-term supplementation of vitamin D could decrease the risk or inhibit the growth of UFs.

Therefore, we aim to conduct a randomised clinical trial and evaluate the effect and safety of administration with vitamin D on decreasing the risk and inhibiting the development of UFs in reproductive-aged women.

METHODS AND ANALYSIS

Study design

This is an open-label, randomised controlled trial. The study contains two parts (part I and part II) and will be conducted between 31 May 2020 and 1 October 2022 in the Second Affiliated Hospital of Wenzhou Medical University, a hospital in China. Part I is to investigate the effect of supplementation with vitamin D on the risk of UFs. Part II is about the association between vitamin D supplementation and the development of UFs. The regimen of vitamin D doses from several international guidelines and important published clinical trials are listed in table 1.

Part I: efficacy of vitamin D on the risk of UFs

Study objectives

The primary objective of this part is to assess the efficacy of supplementation with vitamin D on decreasing the risk of incident UFs within 1 year and 2 years. The secondary objective of this study is to evaluate the safety of supplementation with vitamin D in subjects.

Trial design

This is an open-label, randomised controlled trial. After signing of informed consent, vitamin D deficiency patients (12 ng/mL ≤ serum 25-hydroxyvitamin D$_3$ ≤ 20 ng/mL) without UFs will be randomly assigned in a 1:1 ratio to either the intervention group A or the control group B. Intervention group A will receive an oral dose of 1600 IU (four capsules)/day vitamin D$_3$ for up to 2 years. Control group B will receive 2 years follow-up. Patients with vitamin D insufficiency (21 ng/mL ≤ serum 25-hydroxyvitamin D$_3$ ≤ 29 ng/mL) without UFs will be randomly assigned in a 1:1 ratio to intervention group C or control group D. Intervention group C will accept an oral dose of 800 IU (two capsules)/day vitamin D$_3$ for up to 2 years. Control group D will receive 2 years follow-up. Gynaecological ultrasound examinations will be performed every 6 months. The number, location and size of the UFs will be documented. The safety of subjects will be evaluated, including blood routine examination, electrolyte, hepatic and renal function, liver and urinary system ultrasound, and serum 25-hydroxyvitamin D$_3$. Vitamin D receptor genotype of all patients will also be tested. Vitamin D$_3$ soft capsules (400 IU per capsule) are purchased from Sinopharm star shark pharmaceutical (Xiamen, China) and can be preserved for 2 years. An overview of the study design is shown in figure 1 and table 2.

Sample size

The planned sample size is estimated based on the data from a previous study, in which the UFs incidence was
1.278% per year in Asia and 3.745% per year in African-American women. Women over the age of 40 years are more likely to have UFs.1 A study also revealed that African-American females had lower level of serum 25-hydroxyvitamin D3 as compared with Caucasian females.28 Vitamin D deficiency is shown to increase the risk of UFs in vitro, in vivo animal models and in a small-sample clinical trial. We assume a one-tailed α error of 0.05 and a power (1-β) of 0.8. If the rates are 3.745% for the control group and 1.278% for the intervention group, we allow for a dropout rate of 10% for an effective sample size of 2108 and propose to enrol 2320 participants (580 randomised to each arm).

### Inclusion criteria

1. Volunteers to participate in the study with an informed consent.
2. Married females aged 35–50 who are confirmed with a normal, fibroid-free uterine structure, by means of transvaginal ultrasonography.
3. Serum 25-hydroxyvitamin D3 ≥12 ng/mL, ≤29 ng/mL.

### Exclusion criteria

1. Women with serum 25-hydroxyvitamin D3 <12 ng/mL or >29 ng/mL.
2. Body mass index (BMI) <18.5 kg/m² or BMI >25 kg/m².
3. Use of sexual hormone, mifepristone, GnRHa or other medications, which are likely to interfere with UFs in the past 3 months.
4. Pregnancy, lactation, postmenopause or planned pregnancy within 2 years.
5. Allergic to vitamin D3 soft capsules.
6. Suspected or identified as other tumours of genital tract.
7. History of hysterectomy or myomectomy.
8. History of osteoporosis or vitamin D deficiency taking vitamin D supplements constantly within previous 1 month.
9. History of hyperparathyroidism, infectious diseases (tuberculosis, AIDS), autoimmune disease or others.

### Table 1 The doses of vitamin D supplementation in different clinical trials published since 2010

<table>
<thead>
<tr>
<th>Group</th>
<th>Country</th>
<th>Population</th>
<th>Age (years)</th>
<th>Oral vitamin D</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Holick et al</td>
<td>USA</td>
<td>General population</td>
<td>&gt;19</td>
<td>Risk of vitamin D deficiency: 1500–2000 IU/day; vitamin D deficiency: 50000 IU/wk for 8 weeks, followed by maintenance therapy of 1500–2000 IU/day</td>
<td>32</td>
</tr>
<tr>
<td>de Boer et al</td>
<td>USA</td>
<td>Participants with type 2 diabetes</td>
<td>Men aged ≥50 and women aged ≥55</td>
<td>Vitamin D3 (cholecalciferol 2000 IU/day) and matching inert placebo</td>
<td>38</td>
</tr>
<tr>
<td>Burt et al</td>
<td>Canada</td>
<td>Healthy adults without osteoporosis</td>
<td>55–70</td>
<td>Vitamin D3 at 400 IU/day (n=109), or 4000 IU/day (n=100), or 10000 IU/day (n=102) for 3 years</td>
<td>39</td>
</tr>
<tr>
<td>Urashima et al</td>
<td>Japan</td>
<td>Patients with digestive tract cancers overall</td>
<td>30–90</td>
<td>Vitamin D 2000 IU/day and matching placebo</td>
<td>40</td>
</tr>
<tr>
<td>Scragg et al</td>
<td>New Zealand</td>
<td>General population</td>
<td>50–84</td>
<td>Vitamin D at initial bolus dose of 200000 IU, followed by maintenance dose of 100000 IU/month</td>
<td>41</td>
</tr>
<tr>
<td>Aglipay et al</td>
<td>Canada</td>
<td>Children</td>
<td>1–5</td>
<td>Vitamin D at doses of 2000 IU/day (n=349) and 400 IU/day (n=354)</td>
<td>42</td>
</tr>
<tr>
<td>Zittermann et al</td>
<td>Germany</td>
<td>Heart failure patients</td>
<td>18–79</td>
<td>Patient with serum 25-hydroxyvitamin D3 level &lt;75 nmol/L were randomised to receive 4000 IU/day vitamin D or matching placebo for 3 years</td>
<td>43</td>
</tr>
<tr>
<td>Lappe et al</td>
<td>USA</td>
<td>Postmenopausal women</td>
<td>≥55</td>
<td>Treatment group: 2000 IU/day vitamin D3 and 1500 mg/day calcium; The placebo group: identical placebos</td>
<td>44</td>
</tr>
<tr>
<td>Arora et al</td>
<td>USA</td>
<td>Low vitamin D status</td>
<td>18–50</td>
<td>High-dose group: 4000 IU/day for 6 months; low-dose group: 400 IU/day for 6 months</td>
<td>45</td>
</tr>
<tr>
<td>Rusinska et al</td>
<td>Poland</td>
<td>Healthy adults</td>
<td>19–65</td>
<td>800–2000 IU/day</td>
<td>46</td>
</tr>
</tbody>
</table>

SBP, systolic blood pressure.

10. Alanine aminotransferase (ALT) or aspartate transaminase (AST) more than 3 times of the normal upper limit, total bilirubin (TBIL) more than 2 times of the normal upper limit.

11. Creatinine levels ≥1.4 mg/dL (123 μmol/l) or creatinine clearance ≤50 mL/min.


13. Simultaneous participation in another clinical study with investigational medicinal product(s).

Outcomes measures

The primary outcome is the first diagnosis of UFs in different groups. The secondary outcomes include hypercalcaemia, abnormal liver and renal function, and urinary calculus in different groups. Transvaginal ultrasound examinations will be performed by a well-experienced physician in gynaecology. If possible, the same examiner should conduct all examinations of a subject and the same ultrasound machine should be used throughout the study.

Withdrawal

Subjects must be withdrawn from the study when one of the following criteria occurs:

1. At their own request. At any time during the study and without giving reasons, a subject may decline to participate further. The subject will not suffer any disadvantages as a result.

2. In the investigator’s opinion, continuation of the study treatment would be harmful to the subject’s health.

3. Patients with poor compliance.

4. Lost to follow-up.

5. Pregnancy.

6. Receive other medical treatments which may affect the level of serum 25-hydroxyvitamin D3 or other surgical treatments.

7. The level of serum calcium >3.5 mmol/L or serum 25-hydroxyvitamin D3 >150 ng/mL.

Safety assessments

Safety of vitamin D administrated in patients without UFs will be assessed by renal and liver function test, serum electrolyte (sodium, chloride, potassium, calcium and phosphorus), blood routine test and serum 25-hydroxyvitamin D3. Urine pregnancy test and serum 25-hydroxyvitamin D3 level will be detected every 3 months. Other indicators will be detected during the period of screening and after the treatment of every 6 months. Liver and urinary system ultrasound will be conducted after the treatment of 12 months and 24 months. The occurrence of any adverse events in trial participants will be recorded in the case report forms during each patient visit. Patients will be withdrawn who have severe adverse events, as it is unsafe for them to continue the trial. Meanwhile, we will give them relevant medical care and follow them up until the reaction has terminated.

Part II: association between vitamin D and the development of UFs

Study objectives

The primary objective of this part is to assess the association of supplementation with vitamin D on inhibiting digestive system diseases (malabsorption, Crohn’s disease and dysentery).
the development of UFs within 1 year and 2 years. The secondary objective of part II is to evaluate the safety of supplementation with vitamin D in UFs subjects.

Trial design

After signing of informed consent, UFs patients with vitamin D deficiency (12 ng/mL ≤ serum 25-hydroxyvitamin D₃ ≤ 20 ng/mL) will be randomly assigned in a 1:1 ratio to intervention group A or control group B. Intervention group A will accept an oral dose of 1600 IU (four capsules)/day vitamin D₃ for up to 2 years. Control group B will receive 2-year follow-up. UFs patients with vitamin D insufficiency (21 ng/mL ≤ serum 25-hydroxyvitamin D₃ ≤ 29 ng/mL) will be randomly assigned in a 1:1 ratio to intervention group C or control group D. Intervention group C will accept an oral dose of 800 IU (two capsules)/day vitamin D₃ for up to 2 years. Control group D will receive 2-year follow-up. Gynaecological ultrasound examinations will be performed every 3 months. The number, location and size of the UFs will be documented (the transverse, longitudinal and antero–posterior diameters of fibroids will be documented at each efficacy ultrasound examination for volume calculation). The safety of vitamin D in subjects with UFs will be evaluated, including blood routine examination, serum electrolyte, hepatic and renal function, liver and urinary system ultrasound, and serum 25-hydroxyvitamin D₃. Vitamin D₃ soft capsules (400 IU per capsule) are purchased from Sinopharm star shark pharmaceutical (Xiamen, China). An overview of the study design is shown in figure 2 and table 3.

Sample size

According to a previous study, the volume of UFs was 8.2 (2.1–30.5) cm³ after the supplement of vitamin D for 12 months and 11.4 (5.5–22.3) cm³ in the control group after 12 months follow-up, respectively. On the basis of a 0.9 power to detect a significant difference (α=0.05, one sided), 320 participants will be required for the four groups in a 1:1:1:1 ratio. Allowing for a 10% withdrawal rate, we plan to enrol 360 patients in the whole trial (90 randomised to each arm).

Inclusion criteria

1. Patients are willing to cooperate with the follow-up and sign an informed consent.
2. Married females aged 35–50 who are diagnosed as UFs by transvaginal ultrasonography.
3. The maximum average diameter of intramural myoma is ≤ 4 cm, ≥ 1 cm.
4. Serum 25-hydroxyvitamin D₃ ≥12 ng/mL, ≤ 29 ng/mL.

Exclusion criteria

1. Women with serum 25-hydroxyvitamin D₃ <12 ng/mL or >29 ng/mL.
2. BMI <18.5 kg/m² or BMI >25 kg/m².
3. Patients with heavy menstrual bleeding (>80.0 mL) per menstrual period, menstrual disorders, pelvic discomfort, infertility or other indications for operation.
4. Patients complicated with leiomyoma degeneration and adenomyosis that were suspected or diagnosed by transvaginal ultrasound or gynaecological examination.
5. Allergic to vitamin D₃ soft capsules.

<table>
<thead>
<tr>
<th>Table 3 Flow chart of the study showing timing collection of different variables</th>
</tr>
</thead>
<tbody>
<tr>
<td>Follow-up</td>
</tr>
<tr>
<td>Months</td>
</tr>
<tr>
<td>Informed consent</td>
</tr>
<tr>
<td>Medical history</td>
</tr>
<tr>
<td>Physical examination</td>
</tr>
<tr>
<td>Serum 25-hydroxyvitamin D₃</td>
</tr>
<tr>
<td>Urine pregnancy test</td>
</tr>
<tr>
<td>Gynecologic ultrasound</td>
</tr>
<tr>
<td>Hepatic and renal function</td>
</tr>
<tr>
<td>Electrolyte</td>
</tr>
<tr>
<td>Blood routine examination</td>
</tr>
<tr>
<td>Liver and urinary system ultrasound</td>
</tr>
<tr>
<td>Side effect assessment</td>
</tr>
<tr>
<td>Changes in menstruation</td>
</tr>
<tr>
<td>Adverse event assessment</td>
</tr>
<tr>
<td>Vitamin D receptor genotype</td>
</tr>
</tbody>
</table>

Figure 2 Flow chart showing the steps of part II in participant recruitment, treatment and analysis.
6. Use of sexual hormone, mifepristone, GnRHα or other medication which is likely to interfere with UFs in the past 3 months.
7. Pregnancy, lactation, postmenopause or planned pregnancy within 2 years.
8. Suspected or identified as other tumours of genital tract.
9. History of osteoporosis or vitamin D deficiency taking vitamin D supplements within previous 1 month.
11. ALT or AST more than 3 times of the normal upper limit, TBIL more than 2 times of the normal upper limit.
12. Creatinine levels ≥1.4 mg/dL (123 μmol/l) or creatinine clearance ≤50 mL/min.
14. Some cases those uteruses are difficult to scan or the amount of UFs is more than 4.
15. Simultaneous participation in another clinical study with investigational medicinal product(s).

Outcomes measures
Primary outcomes: percent change in volume of the largest fibroid and total fibroids compared with baseline (baseline=last value obtained before randomisation; measured by ultrasound examination). The volume of the largest uterine leiomyoma (in cm³) was calculated with the following formula:

\[
\text{volume} = \frac{4\pi}{3} \times \frac{a}{2} \times \frac{b}{2} \times \frac{c}{2} = \frac{\pi \cdot a \cdot b \cdot c}{6}
\]

Secondary outcomes: percentage of subjects undergoing other medical or surgical treatment, hypercalcaemia, urinary calculus, abnormal liver and renal function. Transvaginal ultrasound examinations will be performed by a well-experienced gynaecologist. If possible, the same examiner should conduct all examinations for each subject throughout the study and the same ultrasound machine should be used throughout the study.

Withdrawal
Subjects must be withdrawn from the study when one of the following criteria occurs:
1. At their own request. At any time during the study and without giving reasons, a subject may decline to participate further. The subject will not suffer any disadvantages as a result.
2. In the investigator’s opinion, continuation of the study treatment would be harmful to the subject’s health.
3. Patients with poor compliance.
4. Lost to follow-up.
5. Pregnancy.
6. Other medical or surgical treatments for UFs.
7. Receive other medical treatments which may affect the level of serum 25-hydroxyvitamin D₃ or other surgical treatments.
8. The level of serum calcium >3.5 mmol/L or serum 25-hydroxyvitamin D₃ >150 ng/mL.

Safety assessments
Safety of vitamin D administrated in patients with UFs will be assessed by the same methods as part I.

Treatment compliance assessment
All research medications (vitamin D₃ soft capsules) should be recorded. Standard with good compliance is defined as: 80% ≤ actual oral dose/dose × 100% ≤ 120%. Criteria for poor compliance is as follows: actual oral dose/dose ≥ 100% ≤ 80% or actual oral dose/dose × 100% ≥ 120%. Each follow-up should be based on the number of returned study drugs to determine the drug compliance. Subjects should return all unused research drugs and empty packages of used drugs every follow-up.

Statistical analysis
Statistical analyses will be performed using SPSS V.22.0 for Windows (SPSS). The randomisation sequence is generated by the use of the random number table. The normal distribution of continuous variables is tested by one-sample Kolmogorov-Smirnov test. Continuous variables with normal distribution are reported as mean (SD); non-normal variables are presented as median (IQR). Means of 2 and 3 or more continuous normally distributed variables, respectively, are compared by independent samples Student’s t-test or one-way analysis of variance test. Mann-Whitney U test and Kruskal-Wallistest are used, respectively, to compare means of 2 and 3 or more groups of variables that are not normally distributed. The frequencies of categorical variables are compared using Pearson \( \chi^2 \) or Fisher’s exact test, when appropriate. A p<0.05 is considered statistical significance.

Ethics and dissemination
The study has been approved by the ethics committee of the Second Affiliated Hospital of Wenzhou Medical University (No. LCKY2018-35) and registered in the United States National Institutes of Health Clinical Trials Registry: NCT03586947 and NCT03584529. The procedure will be performed following the principles described in the declaration of helsinki. We will publish the results of this study in peer-reviewed journals and related websites.

No patient and public involvement
There were no funds or time allocated for patient and public involvement so we were unable to involve patients. We have invited patients to help us develop our dissemination strategy.

DISCUSSION
There is an increasing awareness that vitamin D deficiency is associated with many health outcomes. Up
to now, the roles of vitamin D in calcium homeostasis and bone health have been well characterised. In the last decade, it has been recognised that vitamin D also prevented cardiovascular diseases, infections, adverse pregnancy outcomes and tumours. Nevertheless, the cut-off thresholds for vitamin D deficiency and optimal levels are still controversial. The guideline of The Endocrine Society suggests vitamin D insufficiency is defined as a serum 25-hydroxyvitamin D$_3$ of 21–29 ng/mL, and vitamin D deficiency as a serum 25-hydroxyvitamin D$_3$ below 20 ng/mL. The guideline also recommends that patients with vitamin D deficiency should be treated with 50 000 IU of vitamin D once a week for 8 weeks to achieve a blood level of serum 25-hydroxyvitamin D$_3$ above 30 ng/mL, followed by maintenance therapy of 1500–2000 IU/day. Patients with vitamin D insufficiency require at least 600 IU/day of vitamin D for the prevention of vitamin D deficiency. In fact, the level of serum 25-hydroxyvitamin D$_3$ varies from race to race. It is reported that caucasian females have higher serum 25-hydroxyvitamin D$_3$ concentrations than the others. According to the guideline of Institute of Medicine, however, vitamin D deficiency is defined as a serum 25-hydroxyvitamin D$_3$ below 12 ng/mL, and vitamin D insufficiency as a serum 25-hydroxyvitamin D$_3$ of 12–20 ng/mL. Specialists from Osteoporosis Committee of China Gerontological Society recommend that patients with high risks (history of osteoporosis, inadequate sun exposure, use of glucocorticoid, etc) whose blood levels of serum 25-hydroxyvitamin D$_3$ are between 12 and 20 ng/mL should receive at least 600 IU/day vitamin D supplementation. Patients with blood levels of serum 25-hydroxyvitamin D$_3$ exceed 20 ng/mL could obtain an adequate amount of vitamin D from dietary sources and sun exposure. It is reported that the single-nucleotide polymorphisms in vitamin D receptor genes modified the efficacy of vitamin D$_3$ supplementation to increase circulating serum 25-hydroxyvitamin D$_3$ levels. To determine the potential relationship between them, the vitamin D receptor genotype of all patients will be tested. Females over the age of 35 years are more likely to suffer from UFs. Furthermore, postmenopause and pregnancy might affect the development and progression of UFs. So the females aged 35–50 years are chosen in this trial. We will exclude patients who are pregnant, lactant, postmenopausal, or planned pregnancy within 2 years. In this study, patients with vitamin D deficiency or insufficiency will receive adequate vitamin D supplementation. Dietary vitamin D intake and other supplements of vitamin D will be limited.

In conclusion, this is the first study protocol of an open-label, randomised controlled trial to evaluate the efficacy and safety of vitamin D supplementation in preventing and inhibiting the UFs. However, our study should be interpreted within the context of two limitations. First, the trial is not a double-blind, placebo-controlled trial. Furthermore, another limitation is that the trial is implemented in only one hospital. Notwithstanding these limitations, the results from this study will provide new evidences about vitamin D preparations in UFs from a well-designed trial. Once our hypothesis is confirmed, this study will provide a more effective, safe, and low-cost therapy in the prevention and treatment of UFs.

Correction notice This article has been corrected since it was published. First affiliation has been updated.

Author Contributions XZ is the principal investigator of this study and refined the protocol. SB and YS wrote the manuscript and contributed to the design of the study. SB will recruit the patients and conduct the trial. YS, XZ and YL will supervise the trial. CJ, the medical statistician for the study, will contribute to the statistical design and analysis of data. All authors have revised the protocol critically for important intellectual content and approved the final manuscript.

Funding This work was supported by the clinical trial centre of the Second Affiliated Hospital of Wenzhou Medical University (No. SJH&WMU-CR2017-07-101) and grants from Wenzhou Science and Technology Grant (Y20170804).

Disclaimer Sponsors of the study had no involvement in the collection, analysis, and interpretation of data or the writing of the manuscript.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Xueqiong Zhu http://orcid.org/0000-0002-8389-928X

REFERENCES


